Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice

Abstract

Bexarotene has shown inhibition of lung and mammary gland tumorigenesis in preclinical models and in clinical trials. The main side effects of orally administered bexarotene are hypertriglyceridemia and hypercholesterolemia. We previously demonstrated that aerosolized bexarotene administered by nasal inhalation has potent chemopreventive activity in a lung adenoma preclinical model without causing hypertriglyceridemia. To facilitate its future clinical translation, we modified the formula of the aerosolized bexarotene with a clinically relevant solvent system. This optimized aerosolized bexarotene formulation was tested against lung squamous cell carcinoma mouse model and lung adenocarcinoma mouse model and showed significant chemopreventive effect. This new formula did not cause visible signs of toxicity and did not increase plasma triglycerides or cholesterol. This aerosolized bexarotene was evenly distributed to the mouse lung parenchyma, and it modulated the microenvironment in vivo by increasing the tumor-infiltrating T cell population. RNA sequencing of the lung cancer cell lines demonstrated that multiple pathways are altered by bexarotene. For the first time, these studies demonstrate a new, clinically relevant aerosolized bexarotene formulation that exhibits preventive efficacy against the major subtypes of lung cancer. This approach could be a major advancement in lung cancer prevention for high risk populations, including former and present smokers.

The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer

“…Importantly, with the combination of high anti-tumor efficacy and a favorable safety profile, rexinoids may be utilized in either clinical setting 27 . While recent strategies utilizing novel aerosolized delivery systems for administration of bexarotene have been effective in rodent models of lung cancer without inducing hypertriglyceridemia or hypercholesterolemia 43 , 44 , it is prudent to continue to synthesize new RXR agonists with improved efficacy and toxicity profiles in addition to optimizing drug delivery strategies. A combination of these two strategies may yield the best results.…”

The Landscape of Coronavirus Disease 2019 (COVID-19) and Integrated Analysis SARS-CoV-2 Receptors and Potential Inhibitors in Lung Adenocarcinoma Patients

“…Bexarotene is a synthetic high-affinity retinoid X receptor agonist that is currently used clinically for the treatment of T-cell lymphoma (Talpur et al, 2002). In preclinical mouse models, bexarotene has also been confirmed to inhibit the occurrence of lung tumors (Zhang et al, 2019). Some studies have demonstrated that bexarotene exerts anti-inflammatory effects by downregulating the expression of interleukin (IL)-6, IL-8, monocyte chemoattractant protein 1 (MCP-1) and high mobility group box-1 (Li et al, 2019).…”

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

“…Reproduced with permission. [ 10 ] Copyright 2019, American Chemical Society. The proportion of driver mutation of SCC and ADC was previously published.…”